10 Common Symptoms of Eosinophilic Granulomatosis with Polyangiitis

Eosinophilic granulomatosis with polyangiitis, often called EGPA, is a rare condition that can affect the lungs, sinuses, skin, nerves, heart, kidneys, and digestive system. It happens when inflammation damages small to medium blood vessels, while eosinophils, a type of white blood cell linked to allergic disease, become unusually high. Because EGPA can touch many organs, its symptoms may look confusing at first.

One reason EGPA is often missed is that it may begin like long-lasting asthma, allergies, or sinus trouble. A person may deal with wheezing, nasal congestion, coughing, or repeated sinus infections before more serious signs appear. Later, symptoms such as numbness, skin rashes, chest discomfort, fatigue, fever, stomach pain, or unexplained weight loss may suggest that inflammation is spreading beyond the airways.

The condition is uncommon, which makes awareness even more important. Studies estimate that EGPA affects about 2 to 38 people per 1 million, with incidence often reported below 4 new cases per million people each year. This means many patients and even some non-specialists may not see it often, but delayed recognition can allow organ damage to progress.

EGPA can develop in phases, but not everyone follows the same pattern. Some people first notice asthma and sinus symptoms. This article explores 10 common symptoms of eosinophilic granulomatosis with polyangiitis, explains why they may occur, and helps readers understand when symptoms should be taken seriously. Knowing these signs does not replace a diagnosis, but it can make the path to proper testing and treatment clearer.

Table of Contents

What is Eosinophilic Granulomatosis with Polyangiitis (EGPA)?

Eosinophilic Granulomatosis with Polyangiitis (EGPA), historically known as Churg-Strauss syndrome, is a rare and complex systemic autoimmune disease primarily defined by the inflammation of small to medium-sized blood vessels (vasculitis).

This condition is a member of a group of diseases called ANCA-associated vasculitides, and its hallmark features are severe asthma, abnormally high levels of eosinophils in the blood and tissues, and multi-system organ damage resulting from vasculitis. The inflammation restricts blood flow to vital organs and tissues, leading to a wide spectrum of clinical manifestations that can range from mild to life-threatening.

Three Distinct Phases of EGPA

The three distinct phases of EGPA are the allergic (or prodromal) phase, the eosinophilic phase, and the vasculitic phase, which represent a typical, though not universal, progression of the disease over time.

This phased development is a key characteristic of EGPA and helps explain why diagnosis can be delayed, as early symptoms may not immediately suggest a systemic autoimmune disorder. Each phase is defined by a dominant clinical feature, although there can be significant overlap between them, and not every patient experiences this classic sequence.

More specifically, in phase 1, the Allergic (Prodromal) Phase: This is often the initial stage and can last for many years, sometimes even decades, before other symptoms appear. The primary manifestations are respiratory and allergic in nature. The most common feature is the development of adult-onset asthma, which is often severe and may be difficult to control with standard therapies.

Patients may also experience allergic rhinitis (hay fever), characterized by a runny nose, sneezing, and nasal congestion, as well as chronic rhinosinusitis. The development of nasal polyps, noncancerous growths lining the nasal passages or sinuses, is also very common during this phase. Because these conditions are widespread in the general population, EGPA is rarely suspected at this early stage.

In phase 2, the disease’s namesake cells, eosinophils, become the central problem. Eosinophils are a type of disease-fighting white blood cell, but in EGPA, the immune system produces them in excessively high numbers, a condition known as hypereosinophilia. These excess eosinophils infiltrate various organs and tissues, causing direct inflammatory damage.

The lungs and gastrointestinal tract are most commonly affected. This infiltration can lead to eosinophilic pneumonia (inflammation in the lungs) or eosinophilic gastroenteritis (inflammation of the stomach and intestines), causing symptoms like coughing, shortness of breath, abdominal pain, and diarrhea. This phase marks the transition from a localized allergic disease to a systemic inflammatory condition.

In phase 3, the vasculitic phase is the most severe and defining stage of EGPA, where widespread inflammation of blood vessels (systemic vasculitis) occurs. This inflammation can narrow, weaken, or block blood vessels, starving tissues and organs of essential oxygen and nutrients. The vasculitic phase is often accompanied by constitutional symptoms like fever, fatigue, unintentional weight loss, and muscle/joint pain.

Critically, this is the stage where severe, life-threatening organ damage can occur. Common targets include the peripheral nerves (causing neuropathy), the skin (leading to rashes and sores), the heart (causing myocarditis or heart failure), and the kidneys. The presence of systemic vasculitis is what ultimately confirms the diagnosis of EGPA.

Is Eosinophilic Granulomatosis with Polyangiitis a Type of Cancer?

Eosinophilic Granulomatosis with Polyangiitis is not a type of cancer; it is a systemic autoimmune disorder characterized by inflammation, not the uncontrolled, malignant growth of cells that defines cancer.

While EGPA involves the overproduction and abnormal behavior of a specific type of white blood cell (eosinophils), the underlying mechanism is fundamentally different from that of a malignancy like leukemia or lymphoma. The confusion often arises because both conditions can involve abnormal blood cell counts and may sometimes share treatment modalities.

To illustrate, in EGPA, the immune system mistakenly identifies the body’s own blood vessels and tissues as foreign invaders. This triggers an inflammatory response, leading to the recruitment and activation of eosinophils, which then cause damage. The process is one of autoimmunity and inflammation. In contrast, cancer is a disease of uncontrolled cell proliferation.

Malignant cells acquire genetic mutations that allow them to grow and divide without restraint, forming tumors and invading other parts of the body (metastasis). The eosinophil overproduction in EGPA is a reactive process driven by immune dysregulation, not a primary clonal or malignant growth.

The eosinophils in EGPA are structurally normal cells that are being produced in excess and are inappropriately activated by the immune system. In a hematologic cancer like chronic eosinophilic leukemia, the eosinophils themselves are cancerous (neoplastic) and arise from a single mutated stem cell. Pathologists can often distinguish between reactive and neoplastic eosinophilia through bone marrow analysis and genetic testing.

Although some powerful immunosuppressive drugs used to treat severe vasculitis (like cyclophosphamide) are also used in chemotherapy for cancer, their purpose is different. In EGPA, these drugs are used to suppress the overactive immune system and halt the inflammatory attack. In cancer treatment, their primary goal is to kill rapidly dividing malignant cells. The mainstay of treatment for EGPA typically involves corticosteroids and other immunomodulatory therapies aimed at controlling inflammation, which is distinct from the cytotoxic approach central to oncology.

10 Common Symptoms of Eosinophilic Granulomatosis with Polyangiitis

Asthma

This is the cornerstone symptom of EGPA, occurring in over 95% of patients. Unlike typical childhood asthma, the asthma associated with EGPA often develops in adolescence or adulthood. It tends to be severe and may prove resistant to conventional treatments like inhaled corticosteroids and bronchodilators. Patients may experience persistent wheezing, coughing, shortness of breath, and chest tightness.

For many, the diagnosis of asthma predates the diagnosis of EGPA by several years or even decades. A key clinical clue is the requirement for oral corticosteroids (like prednisone) to control asthma symptoms, which can sometimes mask the progression to the later, more systemic phases of EGPA. When the vasculitic phase begins, some patients paradoxically report an improvement in their asthma symptoms, which can be a misleading sign.

Allergic Rhinitis/Sinusitis

Chronic inflammation of the upper airways is another hallmark of the allergic phase. Patients frequently suffer from allergic rhinitis (hay fever), leading to symptoms such as a persistent runny nose, nasal congestion, sneezing, and an itchy palate. This often progresses to chronic sinusitis, which involves inflammation of the sinus cavities, causing facial pain or pressure, headaches, and thick nasal discharge.

A very common finding in patients with EGPA is the presence of nasal polyps, which are teardrop-shaped, non-cancerous growths in the nose or sinuses. These polyps can obstruct nasal passages, leading to a reduced sense of smell and further breathing difficulties. Recurrent sinusitis and the need for sinus surgery to remove polyps are common occurrences in the years leading up to a full EGPA diagnosis.

Nerve Pain (Neuropathy)

Peripheral neuropathy affects up to 75% of individuals with EGPA and is a major source of pain and disability. The most common pattern is mononeuritis multiplex, a condition where inflammation damages individual, non-contiguous nerves in a stepwise fashion. This can cause a sudden onset of symptoms in a specific nerve distribution, such as weakness, numbness, and severe burning or shooting pain.

A classic example is foot drop, an inability to lift the front part of the foot due to damage to the peroneal nerve, or wrist drop, caused by damage to the radial nerve. Over time, this can evolve into a more symmetrical polyneuropathy, affecting both hands and feet in a stocking-glove pattern of sensory loss and weakness. Early recognition and treatment are crucial to prevent permanent nerve damage.

Skin Rashes and Sores

The skin is involved in about two-thirds of EGPA cases, offering visible clues to the underlying vasculitis. The manifestations are varied and can include several types of lesions. The most common is palpable purpura, which appears as raised, reddish-purple spots, usually on the lower legs and feet. These spots are caused by blood leaking from inflamed small vessels into the skin and do not blanch (turn white) when pressed.

Another common sign is the development of subcutaneous nodules, which are firm, often tender lumps under the skin, typically found on the scalp, elbows, and hands. In more severe cases, vasculitis can lead to skin ulcerations or sores that are painful and slow to heal. Livedo reticularis, a mottled, net-like pattern on the skin, may also occur.

Fever and Fatigue

A persistent, low-grade fever that is not attributable to an infection is a common sign of the systemic inflammation driving EGPA. It reflects the body’s immune system being in a constant state of high alert.

Alongside this, patients often experience profound and debilitating fatigue. This is not ordinary tiredness; it is a pervasive sense of exhaustion that is not relieved by sleep or rest and can significantly impair one’s ability to perform daily activities, work, and maintain a social life. This overwhelming fatigue is a direct consequence of the chronic inflammatory state and the metabolic demands it places on the body.

Unexplained Weight Loss

Noticeable and unintentional weight loss is another key constitutional symptom. This weight loss is typically caused by a combination of factors. The systemic inflammation itself can increase the body’s metabolic rate, burning more calories at rest.

Furthermore, many patients experience a loss of appetite (anorexia) as a result of feeling generally unwell. If the gastrointestinal tract is involved, malabsorption of nutrients can also contribute to weight loss. Losing a significant amount of weight without trying is a serious sign that warrants immediate medical investigation.

Muscle and Joint Pain

Widespread aches and pains are very common in active EGPA. Myalgia, or diffuse muscle pain, can make the body feel sore and weak, similar to having a severe case of the flu. Arthralgia, or joint pain, is also frequently reported.

The pain can affect multiple joints, often in a symmetrical pattern, and may be migratory, moving from one joint to another. While the joints can become swollen and tender, the arthritis associated with EGPA is typically non-erosive, meaning it does not usually cause the permanent joint destruction seen in conditions like rheumatoid arthritis.

Abdominal Pain

The gastrointestinal (GI) tract is affected in a significant portion of patients. Eosinophils can infiltrate the walls of the stomach and intestines, leading to eosinophilic gastroenteritis. This can cause a range of symptoms, including nausea, vomiting, diarrhea, and severe, crampy abdominal pain.

If vasculitis affects the blood vessels supplying the GI tract, it can lead to more severe complications, such as bleeding (resulting in bloody stools or vomiting blood) or, in rare cases, bowel ischemia (lack of blood flow) and perforation (a hole in the bowel wall), which is a surgical emergency.

Heart Problems

Cardiac involvement is a grave concern in EGPA and a primary determinant of a patient’s prognosis. The most common issue is eosinophilic myocarditis, which is inflammation of the heart muscle. This can impair the heart’s ability to pump blood effectively, leading to symptoms of heart failure such as shortness of breath (especially with exertion or when lying down), swelling in the legs (edema), and fatigue.

Other potential cardiac complications include pericarditis (inflammation of the sac surrounding the heart, causing sharp chest pain), coronary arteritis (inflammation of the heart’s own arteries, which can lead to a heart attack), and valvular problems. Because these symptoms can be subtle at first, routine cardiac screening is essential for all EGPA patients.

Kidney Issues

While the kidneys can be affected by EGPA, significant renal disease is less common and typically less severe than in other related ANCA-associated vasculitides, such as Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA). When kidney involvement does occur, it is usually in the form of glomerulonephritis, which is inflammation of the tiny filtering units within the kidneys.

This may not cause obvious symptoms initially but can be detected through urine tests showing blood (hematuria) or protein (proteinuria). In some cases, it can lead to high blood pressure and impaired kidney function, but progression to end-stage renal failure requiring dialysis is relatively rare in EGPA compared to its sister diseases.

EGPA Diagnosis

The diagnosis of EGPA is not based on a single test but rather a constellation of findings from various diagnostic tools that build a compelling clinical picture. Initially, blood tests are fundamental; a complete blood count (CBC) with differential is performed to identify eosinophilia, which is a hallmark of the disease, defined as an eosinophil count greater than 1,500 cells per microliter or more than 10% of the total white blood cell count.

Another crucial blood test screens for anti-neutrophil cytoplasmic autoantibodies (ANCA), specifically the MPO-ANCA subtype, which is present in about 30-40% of patients and is highly suggestive of the vasculitic component of the disease. Imaging studies are also vital for assessing organ involvement. A chest X-ray or a more detailed computed tomography (CT) scan of the lungs can reveal shifting, patchy opacities or nodules that indicate pulmonary inflammation.

Sinus CT scans may also be used to evaluate chronic sinusitis and nasal polyps. The most definitive diagnostic test, however, is a tissue biopsy. A sample taken from an affected site such as the skin, lung, or a peripheral nerve, is examined under a microscope. A positive biopsy will show the characteristic features of EGPA: eosinophil-rich inflammation, granulomas (collections of inflammatory cells), and necrotizing vasculitis (inflammation and damage to blood vessel walls).

EGPA vs. Granulomatosis with Polyangiitis (GPA)

While both EGPA and Granulomatosis with Polyangiitis (GPA) are forms of ANCA-associated vasculitis that involve inflammation of small- to medium-sized blood vessels, they have distinct clinical presentations and pathological features. The primary difference lies in the prominent allergic and eosinophilic components of EGPA, which are typically absent in GPA.

EGPA is almost always preceded by a history of adult-onset asthma, allergic rhinitis, and significant peripheral eosinophilia. In contrast, GPA is classically characterized by severe upper and lower respiratory tract disease and kidney damage. Patients with GPA often experience destructive sinusitis, nasal septum perforation, and saddle-nose deformity, along with lung nodules that can cavitate (form hollow spaces).

While both conditions can affect the kidneys, the glomerulonephritis in GPA is often more aggressive and destructive. The type of ANCA present also differs; EGPA is more commonly associated with antibodies against myeloperoxidase (MPO-ANCA), while GPA is predominantly linked to antibodies against proteinase 3 (PR3-ANCA).

The Significance of Being ANCA-positive versus ANCA-negative in EGPA

The presence or absence of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with EGPA has significant clinical implications, leading to the classification of two distinct disease phenotypes.

Approximately 30-40% of individuals with EGPA are ANCA-positive, most commonly with the MPO-ANCA subtype. This group tends to exhibit a more vasculitic disease profile. These patients are more likely to experience symptoms directly related to blood vessel inflammation, such as mononeuritis multiplex (nerve damage causing pain, numbness, and weakness), skin manifestations like palpable purpura (raised purple spots), and glomerulonephritis (kidney inflammation).

The disease mechanism in this subgroup is thought to be more closely aligned with other ANCA-associated vasculitides, where the autoantibodies directly contribute to endothelial damage. In contrast, the majority of EGPA patients (60-70%) are ANCA-negative. This subgroup is characterized by an eosinophilic phenotype, where organ damage is driven primarily by direct tissue infiltration of eosinophils rather than antibody-mediated vasculitis.

These individuals are more prone to developing cardiac complications, such as myocarditis (inflammation of the heart muscle) and heart failure, as well as more severe pulmonary involvement, including lung infiltrates. Understanding a patient’s ANCA status is therefore crucial, as it helps predict the likely pattern of organ involvement, informs prognosis, and can guide therapeutic decisions, with ANCA-positive patients often requiring more aggressive immunosuppression to control the vasculitis.

Can you Have EGPA Without Having Asthma?

While having EGPA without a history of asthma is technically possible, it is exceptionally rare and represents a significant deviation from the classic disease presentation.

Asthma, particularly adult-onset and often severe, is considered a cardinal feature and a core diagnostic criterion for EGPA. It is present in over 95% of diagnosed cases and is typically the first manifestation of the disease, often preceding the systemic vasculitic phase by several years or even decades. The American College of Rheumatology (ACR) 1990 classification criteria for EGPA list asthma as one of the six main factors, and its presence provides a strong indication for the diagnosis.

The more recent 2022 ACR/EULAR classification criteria also heavily weight asthma and obstructive airway disease. In the rare instance where a patient presents with eosinophilia and systemic vasculitis but lacks a history of asthma, the diagnosis of EGPA becomes very challenging. Clinicians would require compelling evidence from other sources to confirm the diagnosis.

This would typically necessitate a tissue biopsy that unequivocally shows both eosinophilic infiltration and necrotizing vasculitis, alongside other supporting features like mononeuritis multiplex or sino-nasal abnormalities. Such cases force a broader differential diagnosis, including other eosinophilic syndromes and vasculitides, making the diagnostic journey far more complex than in a typical patient with a clear history of allergic respiratory disease.

FAQs

1. Is EGPA life threatening?

Yes, EGPA can be life threatening if it affects major organs such as the heart, lungs, kidneys, brain, or digestive tract. The risk is higher when inflammation is severe or treatment is delayed. With early diagnosis, careful monitoring, corticosteroids, immunosuppressive medicines, and newer biologic treatments, many people can control symptoms and reduce complications.

2. Can EGPA go away?

EGPA usually does not “go away” permanently on its own. Many patients enter remission, which means symptoms improve and inflammation becomes controlled. However, relapse can happen, so long-term follow-up is important. Treatment plans may change over time depending on symptoms, eosinophil levels, organ involvement, and medication response.

3. What age is EGPA diagnosed?

EGPA is most often diagnosed in adults, commonly between the ages of 40 and 60. It can occur earlier or later, but it is less common in children. Many people have a history of asthma, allergies, or chronic sinus problems before EGPA is recognized.

4. What not to eat when eosinophils are high?

There is no single EGPA diet for everyone. If high eosinophils are linked to food allergies or eosinophilic digestive disease, doctors may suggest avoiding trigger foods such as dairy, wheat, eggs, soy, nuts, or seafood. Patients should not remove major food groups without medical guidance, because unnecessary restriction can lead to nutritional problems.

5. Can EGPA affect the brain?

Yes, but brain involvement is less common than lung, sinus, skin, or nerve symptoms. EGPA can affect the nervous system and may cause numbness, tingling, weakness, nerve pain, stroke-like symptoms, seizures, confusion, or severe headaches in rare cases. Any sudden neurological symptom needs urgent medical attention.

Conclusion

Eosinophilic granulomatosis with polyangiitis is rare, but its symptoms can affect many parts of the body. Asthma, sinus problems, nerve pain, rashes, fatigue, fever, chest discomfort, stomach pain, or unexplained weight loss may seem unrelated at first, yet together they can point to a deeper inflammatory condition.

Early recognition matters. With proper testing, specialist care, and long-term treatment, many people with EGPA can manage symptoms, protect organ function, and improve daily life. Anyone with persistent asthma plus unusual whole-body symptoms should seek medical evaluation rather than waiting for the condition to progress.

References

Disclaimer This article is intended for informational and educational purposes only. We are not medical professionals, and this content does not replace professional medical advice, diagnosis, or treatment. We aim to provide reliable resources to help you understand various health conditions and their causes. If you are experiencing persistent, severe, or concerning symptoms, you should seek guidance from a qualified healthcare provider. Read the full Disclaimer here →

10 Common Symptoms of Eosinophilic Granulomatosis with Polyangiitis